ROS1 fusions have been identified across various cancer types, with particular clinical relevance in non-small cell lung cancer (NSCLC) [72,73], where targeted therapies such as crizotinib [74] and entrectinib [75] have demonstrated significant efficacy. Here, ROS1 is linked to non-small cell lung carcinoma.